Clinical benefits of adding olanzapine to 5-HT3 receptor antagonist, NK1 receptor antagonist, and dexamethasone for the prevention of nausea and vomiting in highly emetogenic chemotherapy: a systematic review and meta-analysis of the Clinical Practice Guidelines for Antiemesis 2023 from the Japan Society of Clinical Oncology
International Journal of Clinical Oncology · 2025
DOI: 10.1007/s10147-024-02663-4 ↗Kurz gefasst
Metaanalyse in der Zeitschrift International Journal of Clinical Oncology, 2025. Verfasst von Michiyasu Murakami und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Matsuyama Red Cross Hospital, 1 Bunkyo-cho, Matsuyama-shi, Ehime, 790-8524, Japan. muramichi1959@gmail.com. Hauptthemen laut MEDLINE: Antiemetics, Antineoplastic Agents, Dexamethasone, Nausea. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 28 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Matsuyama Red Cross Hospital, 1 Bunkyo-cho, Matsuyama-shi, Ehime, 790-8524, Japan. muramichi1959@gmail.com.
- Department of Artificial Intelligence and Digital Health Science, Kobe University Graduate School of Medicine, 7-1-48 Minatojimaminamimachi, Chuo-ku, Kobe, 650-0047, Japan.
- Department of Internal Medicine, Division of Medical Oncology & Respiratory Medicine, Shimane University Faculty of Medicine, 89-1 Enya-cho, Izumo, Shimane, Japan.
- Department of Obstetrics and Gynecology, Hamamatsu University School of Medicine, 1‑20‑1 Handayama, Chuo‑Ku, Hamamatsu, Shizuoka, 431‑3192, Japan.
- Department of Gastroenterological Surgery, Osaka International Cancer Institute, 3-1‑69, Osaka, 541‑8567, Japan.
- Department of Pscho-Oncology and Palliative Medicine, Osaka International Cancer Institute, 3-1‑69, Chuo-Ku, Osaka, 541‑8567, Japan.
Zitieren
APA
Murakami, M., Miyata, Y., Nakashima, K., Abe, M., Nishimura, J., Wada, M., Iino, K., Akechi, T., Iihara, H., Imamura, C. K., Okuyama, A., Ozawa, K., Kim, Y. I., Sasaki, H., Satomi, E., Takeda, M., Tanaka, R., Nakamura, N., Noda, M., …, & Nakajima, T. E. (2025). Clinical benefits of adding olanzapine to 5-HT3 receptor antagonist, NK1 receptor antagonist, and dexamethasone for the prevention of nausea and vomiting in highly emetogenic chemotherapy: a systematic review and meta-analysis of the Clinical Practice Guidelines for Antiemesis 2023 from the Japan Society of Clinical Oncology. International Journal of Clinical Oncology. https://doi.org/10.1007/s10147-024-02663-4
Vancouver
Murakami M, Miyata Y, Nakashima K, Abe M, Nishimura J, Wada M, et al. Clinical benefits of adding olanzapine to 5-HT3 receptor antagonist, NK1 receptor antagonist, and dexamethasone for the prevention of nausea and vomiting in highly emetogenic chemotherapy: a systematic review and meta-analysis of the Clinical Practice Guidelines for Antiemesis 2023 from the Japan Society of Clinical Oncology. International Journal of Clinical Oncology. 2025. doi:10.1007/s10147-024-02663-4
BibTeX
@article{Murakami2025,
author = {Murakami, Michiyasu and Miyata, Yoshiharu and Nakashima, Kazuhisa and Abe, Masakazu and Nishimura, Junichi and Wada, Makoto and Iino, Keiko and Akechi, Tatsuo and Iihara, Hirotoshi and Imamura, Chiyo K and Okuyama, Ayako and Ozawa, Keiko and Kim, Yong-Il and Sasaki, Hidenori and Satomi, Eriko and Takeda, Masayuki and Tanaka, Ryuhei and Nakamura, Naoki and Noda, Mayumi and Hayashi, Kazumi and Higashi, Takahiro and Boku, Narikazu and Matsumoto, Koji and Matsumoto, Yoko and Okita, Kenji and Yamamoto, Nobuyuki and Aogi, Kenjiro and Nakajima, Takako Eguchi},
title = {Clinical benefits of adding olanzapine to 5-HT3 receptor antagonist, NK1 receptor antagonist, and dexamethasone for the prevention of nausea and vomiting in highly emetogenic chemotherapy: a systematic review and meta-analysis of the Clinical Practice Guidelines for Antiemesis 2023 from the Japan Society of Clinical Oncology},
journal = {International Journal of Clinical Oncology},
year = {2025},
doi = {10.1007/s10147-024-02663-4}
}
EUVIMED